Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation.

Brennan J Wadsworth, Rachel A Cederberg, Che-Min Lee, Natalie S Firmino, S Elizabeth Franks, Jinhe Pan, Nadine Colpo, Kuo-Shyan Lin, Francois Benard, Kevin L Bennewith

Cancer letters 2020 Nov 28

filter terms:

Hypoxic tumour cells are radiation-resistant and are associated with poor therapeutic outcome. A poorly understood source of tumour hypoxia is unstable perfusion, which exposes tumour cells to varying oxygen tensions over time creating "transiently" hypoxic cells. Evidence suggests that angiotensin II type 1 receptor blockers (ARBs) can improve tumour perfusion by reducing collagen deposition from cancer associated fibroblasts (CAFs). However, the influence of ARBs on transient hypoxia and tumour radiation response is unknown. We tested how the ARBs losartan and telmisartan affected the solid tumour microenvironment, using fluorescent perfusion dyes and positron emission tomography to quantify tumour perfusion, and a combination of hypoxia markers and the hemorheological agent pentoxifylline to assess transient tumour hypoxia. We found CAF-containing tumours have reduced collagen I levels in response to telmisartan, but not losartan. Telmisartan significantly increased tumour blood flow, stabilized microregional tumour perfusion, and decreased tumour hypoxia by reducing the development of transient hypoxia. Telmisartan-treated tumours were more responsive to radiation, indicating that telmisartan reduces a therapeutically important population of transiently hypoxic tumour cells. Our findings indicate telmisartan is capable of modifying the tumour microenvironment to stabilize tumour perfusion, reduce transient hypoxia, and improve tumour radiation response. Copyright © 2020 Elsevier B.V. All rights reserved.

Citation

Brennan J Wadsworth, Rachel A Cederberg, Che-Min Lee, Natalie S Firmino, S Elizabeth Franks, Jinhe Pan, Nadine Colpo, Kuo-Shyan Lin, Francois Benard, Kevin L Bennewith. Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation. Cancer letters. 2020 Nov 28;493:31-40